Fiche publication
Date publication
décembre 2024
Journal
EClinicalMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GRANEL-BROCARD Florence
Tous les auteurs :
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, Leccia MT, Maubec E, Arnault JP, Brunet-Possenti F, De Quatrebarbes J, Granel-Brocard F, Gaudy-Marqueste C, Pages C, Stoebner PE, Saiag P, Lesimple T, Dupuy A, Legoupil D, Montaudié H, Oriano B, Lebbe C, Porcher R
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or for a maximum duration of two years. Prolonged follow-up of responders after treatment cessation shows sustained response and a low risk of relapse in the months following cessation. To date, the optimal duration of anti-PD-1 therapy for metastatic melanoma remains unestablished. The objective of this work was to evaluate the optimal duration of ICI administration.
Mots clés
Advanced melanoma, Duration of treatment, Emulated trial, Immunotherapy
Référence
EClinicalMedicine. 2024 12;78:102960
